Sangamo Therapeutics (NASDAQ:SGMO) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.03), MarketWatch Earnings reports. The business had revenue of $26.30 million for the quarter, compared to the consensus estimate of $24.20 million. Sangamo Therapeutics had a negative net margin of 51.51% and a negative return on equity of 16.32%. The firm’s revenue for the quarter was up 100.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.37) EPS.
SGMO traded down $0.27 during trading on Tuesday, hitting $11.36. The stock had a trading volume of 1,155,468 shares, compared to its average volume of 1,423,760. The firm has a market cap of $1.63 billion, a PE ratio of -18.93 and a beta of 1.97. Sangamo Therapeutics has a 12 month low of $8.27 and a 12 month high of $19.43. The company has a 50 day simple moving average of $11.90 and a 200-day simple moving average of $12.69.
SGMO has been the topic of a number of recent research reports. TheStreet downgraded shares of Sangamo Therapeutics from a “c-” rating to a “d” rating in a report on Thursday, February 25th. Stifel Nicolaus initiated coverage on shares of Sangamo Therapeutics in a report on Tuesday, January 5th. They set a “hold” rating and a $16.00 price target on the stock. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, April 23rd. Wells Fargo & Company cut their price target on shares of Sangamo Therapeutics from $36.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, March 3rd. Finally, Royal Bank of Canada started coverage on shares of Sangamo Therapeutics in a report on Monday. They set an “outperform” rating and a $22.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Sangamo Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $19.29.
In other news, EVP Gary Loeb sold 17,524 shares of the business’s stock in a transaction dated Tuesday, March 23rd. The shares were sold at an average price of $13.13, for a total transaction of $230,090.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.80% of the company’s stock.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression.
Further Reading: How accurate is the Rule of 72?
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.